Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective study from the Belgian Hematology Society (BHS)

Bone Marrow Transplant. 2022 Jan;57(1):116-118. doi: 10.1038/s41409-021-01464-x. Epub 2021 Oct 5.

¹ Section of Hematology, Cliniques Universitaires St-Luc, Université Catholique de Louvain, Brussels, Belgium. Xavier.Poire@uclouvain.be.
² Section of Hematology, CHU UCL Namur-Godinne, Université Catholique de Louvain, Yvoir, Belgium.
³ Data Management Office, Belgian Hematology Society, Liège, Belgium.
⁴ Section of Hematology, Centre Hospitalier Universitaire de Liège, Université de Liège, Liège, Belgium.
⁵ Department of Hematology, University Hospitals of Leuven and KU Leuven, Leuven, Belgium.
⁶ Section of Hematology, Institut Jules Bordet, Université libre de Bruxelles, Brussels, Belgium.
⁷ Department Clinical Hematology, Universitair Ziekenhuis Brussel, Brussels, Belgium.
⁸ Department of Hematology, AZ Delta, Roeselare, Belgium.
⁹ Department of Hematology, Antwerp University Hospital, Edegem, Belgium.
¹⁰ Department of Hematology, Ghent University Hospital, Ghent, Belgium.
¹¹ Department of Hematology, ZNA Stuivenberg, Antwerp, Belgium.
¹² Department of Hematology, AZ Sint Jan, Brugge, Belgium.

^# Contributed equally.

No abstract available

Publication types